240 related articles for article (PubMed ID: 16225113)
1. Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment.
Sein Anand J; Chodorowski Z; Hajduk A
Przegl Lek; 2005; 62(6):522-3. PubMed ID: 16225113
[TBL] [Abstract][Full Text] [Related]
2. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?
Rohrer CK; Page RL; Shakar SF; Lindenfeld J
J Card Fail; 2011 Oct; 17(10):875-7. PubMed ID: 21962427
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
5. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
6. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
7. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
9. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
Kaplan SA; Walmsley K; Te AE
J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
11. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?
Sarma AV; Parsons JK; McVary K; Wei JT
J Urol; 2009 Dec; 182(6 Suppl):S32-7. PubMed ID: 19846144
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
13. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
14. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
15. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
16. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia.
Rosen RC
Curr Opin Urol; 2006 Jan; 16(1):11-9. PubMed ID: 16385195
[TBL] [Abstract][Full Text] [Related]
17. (Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Jul; 17(14):3930-4. PubMed ID: 17517507
[TBL] [Abstract][Full Text] [Related]
18. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
Roehrborn CG; Schwinn DA
J Urol; 2004 Mar; 171(3):1029-35. PubMed ID: 14767264
[TBL] [Abstract][Full Text] [Related]
19. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Seftel A; Rosen R; Kuritzky L
Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
[TBL] [Abstract][Full Text] [Related]
20. Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia.
Yokoyama T; Watanabe T; Saika T; Nasu Y; Kumon H; Miyaji Y; Nagai A
Int J Urol; 2007 Jul; 14(7):598-601. PubMed ID: 17645601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
